GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

New enzyme offers cleaner route to more stable diabetes and obesity drugs

Chemistry researchers at the University of Utah have uncovered an enzyme, dubbed PapB, that can "tie off" therapeutic peptides-protein-like drugs-into tight rings, a process known as macrocyclization.

16 Oct 2025

GLP-1 medications found to slow alcohol absorption and lessen intoxication

There's mounting evidence that popular drugs prescribed for diabetes management and weight loss - better known by trade names like Ozempic and Wegovy - could be effective in reducing alcohol use.

15 Oct 2025

In Mississippi, Medicaid coverage of weight loss drugs fails to catch on

April Hines has battled with her weight since she was a teenager. But in the past couple of years, she's fallen from 600 pounds to 385, and her blood pressure and blood sugar levels are down, too. "I'm not as fatigued as I used to be, and I've been able to go back to church," she said.

15 Oct 2025

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.

9 Oct 2025

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

Prediabetes can go into remission without weight loss

Research shows up to 22% of prediabetic individuals achieve remission without weight loss, emphasizing metabolic health over weight loss in diabetes prevention.

2 Oct 2025

Study shows prediabetes remission does not always require weight loss

Remission of prediabetes can occur even without weight loss, protecting against type 2 diabetes in up to 22% of individuals. Metabolic improvements, healthier fat distribution, and enhanced β-cell function, not body weight change, drive this benefit.

30 Sep 2025

Cannabidiol shows promise for obesity and metabolic syndrome

Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use.

29 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Georgia State scientist receives $25,000 grant to develop mechanisms for treating obesity

Chong Hyun Shin, a research associate professor in the Institute for Biomedical Sciences at Georgia State University, has received a $25,000 grant to develop mechanisms for treating obesity and obesity-related metabolic dysfunctions.

23 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale.

19 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025